| A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tube | Bonn, Borstel, Köln | — | rekrutiert |
| A Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Sup | Berlin, Heidelberg | ohne Phasenangabe | rekrutiert |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With | Erlangen, Heidelberg | Phase I | rekrutiert |
| Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler | Heidelberg | — | rekrutiert |
| ColoCare Study - Colorectal Cancer Cohort | Heidelberg | — | rekrutiert |
| DV 100 as a Framework for the Hospital Incident Command System | Heidelberg | — | rekrutiert |
| Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke | Hamburg, Leipzig, Mannheim | ohne Phasenangabe | rekrutiert |
| Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody | Berlin, Essen, Göttingen | Phase III | rekrutiert |
| Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HF | Freiburg im Breisgau, Heidelberg, Leipzig | Phase II | rekrutiert |
| Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock | Berlin, Bonn, Braunschweig | ohne Phasenangabe | rekrutiert |
| Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Mo | Bad Krozingen, Bonn, Dresden | ohne Phasenangabe | rekrutiert |
| Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Pa | Heidelberg | ohne Phasenangabe | rekrutiert |
| Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FL | Heidelberg, Augsburg, Essen | Phase II | rekrutiert |
| Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FAS | Gießen, Hannover, Heidelberg | Phase III | rekrutiert |
| GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | Berlin, Chemnitz, Dresden | Phase II | rekrutiert |
| Heidelberg Registry for Hip and Knee Joint Implants and Revisions | Heidelberg | — | rekrutiert |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdi | Regensburg, Kiel, Aachen | — | rekrutiert |
| Prostate Cancer Patients Treated With Alternative Radiation Oncology Strategies | Heidelberg | ohne Phasenangabe | rekrutiert |
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 | Heidelberg, Erlangen, Frankfurt am Main | Phase III | rekrutiert |
| Registry Study of Proton Radiotherapy in Lymphoma | Heidelberg | — | rekrutiert |
| Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer | Dresden, Heidelberg | — | rekrutiert |
| Sacituzumab Govitecan in Metastatic Colorectal Cancer | Heidelberg | Phase II / Phase III | rekrutiert |
| Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Wh | Düsseldorf, Freiburg im Breisgau, Halle (Saale) | Phase III | rekrutiert |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or | Duisburg, Frankfurt am Main, Freiburg im Breisgau | Phase II | rekrutiert |
| Targeting Real World Usage In Stroke Treatment | Erfurt, Hamburg, Heidelberg | — | rekrutiert |
| The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Reg | Köln, Aachen, Berlin | — | rekrutiert |
| The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) | München, Heidelberg | — | rekrutiert |
| The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resect | Heidelberg, München | — | rekrutiert |
| The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM | Heidelberg, München | — | rekrutiert |
| The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) | München, Heidelberg | — | rekrutiert |
| Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing | Heidelberg | Phase I / Phase II | rekrutiert |